IndyGeneUS sequences clinical and genomic samples and secures participant data on a blockchain ledger to increase transparency and trust for underrepresented groups. The company acquired EncrypGen to operate a marketplace that allows participants to contribute data from services like 23andMe alongside IndyGeneUS’s own sequencing. It operates as a lab resident at Johnson & Johnson’s JLABs and has established a lab in Cape Town to grow African genomic representation. IndyGeneUS aims to create the world’s largest repository of diasporic African clinical and genomic data to improve precision medicine and boost participation of women and people of color in clinical trials. The startup emphasizes transparent, time-stamped ledgers so participants can see how their samples are used, addressing historical mistrust. It was admitted into NYU’s Endless Frontier Labs and plans to launch a seed round in the next two months. Financially, the company has raised just under $2 million in pre-seed funding, including contributions from partner organizations.

Total raised

$2M

Funding rounds

1

Latest round

Seed

Latest activity

Oct 2022